Abiopharma

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

ERAS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

ResMed Inc. Daily Stock Update

Whirlpool Announces Cash Tender Offer Early Results

Communiqué de presse : Le Tzield de Sanofi approuvé aux États-Unis comme première thérapie modificatrice de la maladie pour les patients récemment diagnostiqués avec un diabète de type 1 au stade 3

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

BORR Investors Have Opportunity to Join Borr Drilling Limited Fraud Investigation with the Schall Law Firm

UTHR: Notification

UTHR: Notification

BlackRock ESG Capital Allocation Term Trust (ECAT) Announces Certified Results of 2026 Annual Shareholder Meeting